US Judge Dismisses Gautam Adani Criminal Charges 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
Trump Media Says Truth API Draws 10+ Customers as Conflict Concerns Grow 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Apple Tests China’s CXMT Memory Chips for iPhones and MacBooks Amid AI Supply Crunch 
Natura Q2 Profit Plunges 92% as Financial Expenses Weigh on Earnings 
ADNOC Gas Targets Up to $4B Profit in 2026 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
BOSTON, Feb. 20, 2018 -- resTORbio, Inc. (NASDAQ:TORC), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases, today announced that Joan Mannick, M.D., Chief Medical Officer, will present a company overview at the 2018 RBC Capital Markets Global Healthcare Conference on Thursday, February 22, 2018 at 2:05 p.m. ET in New York.
A live webcast of the presentation can be accessed on the Investors section of resTORbio’s website at http://ir.restorbio.com/investors.
About resTORbio
resTORbio, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. resTORbio’s lead program focuses on selective inhibition of the target of rapamycin complex 1 (TORC1) pathway to treat aging-related diseases with an initial focus on diseases caused by immunosenescence, the decline in immune function that occurs during aging.
Contacts:
Beth DelGiacco
Stern Investor Relations, Inc.
212-362-1200
[email protected]
Michael Lampe
Scient PR
484-575-5040
[email protected]
